The 2014 Breast Cancer Symposium began today in San Francisco, California. This three-day conference brings together oncology professionals to discuss the latest advances in breast cancer research. One of these advances is the identification of two factors that may help better predict the likelihood that breast cancer will come back in the breast or nearby areas like underarm lymph nodes and the chest. These factors are the tumor’s response to chemotherapy given before surgery (neoadjuvant) and the tumor’s subtype.
According to the study’s researchers, the results show that these two factors may be better predictors of local and regional recurrence than the stage of the tumor at diagnosis. The stage describes where a cancer is located, if or where it has spread, and whether it is affecting the functions of other organs in the body.
“Women with large, but not metastatic, cancer of the breast are often treated with chemotherapy before surgery. This study provides new information about the use of tumor stage and the body’s pathologic response to neoadjuvant chemotherapy as predictors of recurrence, which may help guide physician and patient decisions about therapy following surgery,” said Amy Early, MD, FACP, Clinical Professor of Medicine at the University of Buffalo School of Medicine and Biomedical Sciences and Associate Professor of Oncology at Roswell Park Cancer Institute. Dr. Early is also a member of the Board of Directors and chair of the Consensus Committee of the American Society for Breast Disease and a member of the News Planning Team for the 2014 Breast Cancer Symposium.
In this podcast, Dr. Early provides an overview of the results of this study.
Read a full transcript of this podcast.